BioStock: Market report predicts strong growth for Chordate Medical’s technology

About 1 billion people worldwide suffer from migraine making it the third most common disease and the most common neurological disease. Chordate Medical targets the large global migraine market with K.O.S, a neuromodulation treatment technology that is not based on drugs. BioStock contacted Chordate Medical’s CEO Anders Weilandt to get an update on the market potential of the company’s CE-marked treatment system. 

Read the interview with Anders Weilandt at biostock.se: 

https://www.biostock.se/en/2021/09/market-report-predicts-strong-growth-for-chordate-medicals-technology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se